U-M health leaders offer an innovative framework for keeping academic medicine viable
...ile remaining focused on service, productivity and market leadership will shape a positive future for academic medicine," explains Omenn. "We are confident that we will be among those leaders." The editorial recounts how the U-M's health leadership began its course of preventive measures in 1996. At the tim...Expert calls for common sense, science in national response to medicinal herbs
...pulation in the United States with a retail annual market value approximating $4 billion, and the FDA, by es...ity of the long-known herbs and consequent lack of market exclusivity, companies were unwilling to make the substantial investment required to prove their eff...Synthetic rubber kills germs on contact
...l rubber, which he believes may reach the consumer market in a few years. Halosource Corporation of Seattle, Wash., has purchased the process to create antimicrobial plastic, clothing and rubber containing N-halamines. Shelby Davis Worley, Ph.D., is Professor of Chemistry in the Department of Chemi...Nobel Laureate creates potent anticancer weapons
...unforeseen complications, the drug could be on the market in 2002. The natural form of the drug is found in a reef-living animal called Ecteinascidia turbinate, found in the West Indies. It was originally discovered approximately 12 years ago by a former colleague of Corey's from the University of Illinoi...University of Rochester awarded patent for class of drugs known as cox-2 inhibitors
...Pfizer, the pharmaceutical companies which jointly market Celebrex. "We've filed a lawsuit against Searle and Pfizer to ensure that our legal rights are preserved, though we intend to begin discussions with both companies in an effort to negotiate licensing agreements," said Terrance O'Grady, an attorney...FDA approval means Americans with osteoarthritis have a new option
...l anti-inflammatory drug (NSAID) introduced to the market in the past two years, MOBIC is being priced approximately 20 percent less than CELEBREX®* and VIOXX®** for the starting and maintenance daily dose of 7.5 mg. Osteoarthritis -- a painful, debilitating disease that causes cartilage acting ...New approach to antibiotic resistance
...e." More than 100 antibiotics are currently on the market to fight infections, including those suffered by cancer and AIDS patients, people recovering from surgery and others. They work by preventing the growth of bacteria that lead to infections. Wong said the researchers worked with aminoglycosides becaus......l Users -- effects a large portion of the Hispanic market and includes those who base usage on traditions passed on from generation to generation. Can Vitamins or Herbal Remedies Lose Their Efficacy? -- They can, but consumers don't know when products expire because the FDA does not require expiration date...Millennium, Aventis Pharma form novel alliance
...results of operations, views of future industry or market conditions, and other statements that include words like "may," "expects," believes," and "intends," and that describe opinions about future events. Known and unknown risks may cause Millennium's actual results and performances to be materially diff......o-pay amounts assigned to each of the three tiers, market share of preferred drugs, and the approach to selection of tier-three drugs," she said. This study was supported in part by The Agency for Healthcare Research and Quality. Synopses of other presentations from the Express Scripts 2000 Outcomes Confere......uly 24 -- Low-dose contraceptives currently on the market are just as effective as the older, high-dose preparations in protecting women from ovarian cancer, according to investigators from the University of Pittsburgh Graduate School of Public Health (GSPH) in a paper published in the August 1 issue of the...Swiss research team receives American award
...als began the next year, and Diovan arrived on the market in Germany in 1996. Buehlmayer's team included Walter Fuhrer, Pascal Furet, Peter Herold, Bruno Kamber, Hans Kuehnis, Rene Lattmann, Thomas Leutert, Franz Ostermayer, Alfred Sallmann, Tibur Schmidlin and Paul Zbinden. All worked closely with Novartis...California labor market is strong, but workers in poor health don't benefit, UCSF study reports
California's labor market remains strong, according to UCSF researchers. Res...ork have an average of over fifteen years of labor market experience, and 95 percent have at least one year of experience. The researchers report that one in...While California's labor market continues to be strong, Latinos and African Americ...ependent contractors. "Though the California job market is changing and increasing numbers of Californians are working in non-traditional jobs, traditional ...Lawrence Livermore Lab pioneers advanced radiation treatment for cancer
...ood & Drug Administration clearance to produce and market Peregrine systems to the medical community. Secretary of Energy Bill Richardson made the announcement today at NOMOS headquarters. "Peregrine could change the way cancer is treated in America," said Secretary Richardson. "This technology was deve...European commission grants "orphan" status for new acute myeloid leukaemia treatment
...eive incentives for bringing these products to the market and to the patient. Such incentives include the possibility of protocol assistance from the EMEA and fee reductions for all types of centralised marketing authorisation evaluation activities.If approved by the EMEA, Mylotarg would be the first produ......aid. In addition, drug manufacturers aggressively market and physicians widely prescribe a more expensive, related class of drugs - calcium channel blockers -- although many physicians don't realize that these medications are not appropriate substitutes for beta-blockers, Phillips added. Beta-blockers - te...More potent cancer drug made from platinum shows promise in clinical trials
... says Farrell. He believes that it could be on the market as early as 2004. Code-named BBR3464, it belongs to a new class of platinum drugs, which emerged from joint research by Farrell and Novuspharama SpA (formerly Boehringer Mannheim Italia R&D) in Monza, Italy. By manipulating the molecular st...Novartis receives FDA approval for Starlix, a new treatment for type 2 diabetes
... Venezuela. Yamanouchi and Hoechst Marion Roussel market the product in Japan under brand names Starsis or Fastic. Novartis licenses Starlix from Ajinomoto Co. Inc., Japan, and has a co-marketing and co-promotion agreement with Merck KgaA within Europe, and in certain African, Southeast Asian and Latin Am...Wake Forest professor to evaluate managed care patient protection laws
...ly driven corporate strategy, and how do legal and market factors interact with respect to these effects? A...s." Six states reflecting a range of legal and market conditions will be selected for in-depth case studies. These case studies will involve extensive int...